Immune Response BioPharma Sees Partnerships for Blockbuster MS Drug NeuroVax & REMUNE

September 15, 2011 -- Immune Response BioPharma, Inc. Sees Corporate Partnerships for Both Blockbuster MS Drug NeuroVax and HIV/AIDS REMUNE.

“The Immune Response Flag flies high today as we seek to partner NeuroVax a potential blockbuster MS drug as we have entered into discussions with several big pharma potential partners interested in the Multiple Sclerosis vaccine. I would expect one of the larger players to develop NeuroVax, as this is an $18 billion dollar market and a safe effective drug like this would cost big pharma a fortune to develop this type of technology on their own” Mr. Buswell COO IRBP.

“We are also hopeful of a partnership for REMUNE ahead of our meeting with the FDA, a solid partner would be helpful when seeking approval of the HIV/AIDS vaccine. Approval of REMUNE would be a big win for patients, and whomever we partner with this is a billion dollar opportunity for a partner that can manufacture REMUNE on a commercial scale. REMUNE is a monster drug that data proves used as a standalone treatment without HAART has proven to be extremely effective” Mr. Buswell COO IRBP.

“Immune Response BioPharma is a sepsis drug company and will partner NeuroVax and REMUNE to pave the way for our new sepsis drug Sepsicillin a first in class BPI formulation antibiotic. I have dedicated my life to fighting sepsis after my father passed away from sepsis shock, this is a deep personal issue for me, we have a great pipeline and I am just getting warmed up building this company we will get the financing resolved” Mr. Buswell COO IRBP.

Forward-Looking Statement

Some of the statements made in this press release are forward looking in nature. These statements are based on management’s current expectations or beliefs. These forward looking statements are not a guarantee of performance and are subject to a number of uncertainties and other factors, many of which are outside Immune Response BioPharma, Inc.’s control, which could cause actual events to differ materially from those expressed or implied by the statements. The most important factors that could prevent Immune Response BioPharma, Inc. from achieving its stated goals include, but are not limited to: the current uncertainty in the global financial markets and the global economy. Including but not limited to the uncertainties regarding the approval of biopharmaceutical products in a highly regulated market.

Full Press Release Available @ www.immuneresponsebiopharma.com

MORE ON THIS TOPIC